Raymond Brandicourt Olivier's most recent trade in Vaxcyte Inc was a trade of 5,807 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vaxcyte Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 5,807 | 5,807 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 1,148 | 1,148 | - | 0 | Common Stock | |
| BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 22,750 | 22,750 | - | - | Share Option (Right to Buy) | |
| BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 10,985 | 27,326 (0%) | 0% | 0 | Ordinary Shares | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 1,558 | 1,558 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 775 | 775 (0%) | 0% | 0 | Common Stock | |
| Vaxcyte Inc | Raymond Brandicourt Olivier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 40,113 | 40,113 | - | - | Stock Option (right to buy) | |
| BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 34,151 | 34,151 | - | - | Share Option (Right to Buy) | |
| BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 16,341 | 16,341 (0%) | 0% | 0 | Ordinary Shares | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
| BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 27,794 | 27,794 | - | - | Share Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 5,153 | 5,153 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 4,032 | 4,032 | - | - | Stock Option (right to buy) |